Table 2.
Infection | Age, y | No. | TV Prevalence, % (95% CI) | Crude PR (95% CI) |
Adjusted PR (95% CI)a |
Adjusted PR (95% CI)b |
---|---|---|---|---|---|---|
CT | ||||||
Negative | 18–39 | 2115 | 1.2 (.6–2.1) | … | … | … |
Positive | 59 | 0.0 | … | … | … | |
HSV-2 | ||||||
Seronegative | 18–49 | 2506 | 0.3 (.2–.5) | Ref. | Ref. | Ref. |
Seropositive | 494 | 5.5 (3.3–9.1) | 18.6 (10.2–33.8) | 7.1 (3.8–13.3) | 6.0 (2.7–13.3) | |
Genital HPV | ||||||
Negative | 18–59 | 2079 | 0.7 (.3–1.5)c | Ref. | Ref. | Ref. |
Positive | 1634 | 1.8 (1.1–2.9) | 2.6 (1.2–5.4) | 1.6 (.7–3.7) | 1.4 (.6–3.0) |
This analysis reflects all available data for each individual infection. Prevalence ratios of TV infection were estimated from Poisson regression models. P values were determined by the design-adjusted Wald F test. Estimates in bold had a P value <.05.
Abbreviations: CI, confidence interval; CT, Chlamydia trachomatis; HPV, human papillomavirus; HSV-2, herpes simplex virus type 2; PR, prevalence ratio; TV, Trichomonas vaginalis.
aMultivariable model included sex, age, race/ethnicity, educational attainment, and poverty status.
bMultivariable model included sex, age, race/ethnicity, educational attainment, poverty status, and the number of sexual partners in the past 12 months.
cRelative standard error, 36.2%.